Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : 89-Zr CIT-013
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
PET-Based Imaging of Radiolabeled CIT-013
Details : 89-Zr CIT-013 is a Radiolabelled Compounds drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Arthritis, Rheumatoid.
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Inapplicable
August 29, 2025
Lead Product(s) : 89-Zr CIT-013
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CIT-013
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study with CIT-013 in HS Patients
Details : CIT-013 is a Antibody drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Hidradenitis Suppurativa.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
May 28, 2025
Lead Product(s) : CIT-013
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CIT-013
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Johnson & Johnson
Deal Size : $89.2 million
Deal Type : Series B Financing
Citryll Raises EUR 85M to Advance NET-Targeting Therapy for Immune Disorders
Details : The financing will support the company-lead product CIT-013 monoclonal antibody. It is being evaluated for the treatment of rheumatoid arthritis.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
December 09, 2024
Lead Product(s) : CIT-013
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Johnson & Johnson
Deal Size : $89.2 million
Deal Type : Series B Financing
Lead Product(s) : CIT-013
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study With CIT-013 in RA Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
August 22, 2024
Lead Product(s) : CIT-013
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CIT-013
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Citryll Completes Dosing in Phase 1 Trial for Anti-Inflammatory Candidate CIT-013
Details : CIT-013 offers a novel therapeutic approach for treating inflammatory diseases by targeting NETs, which is being investigated for rheumatoid arthiritis.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
July 31, 2024
Lead Product(s) : CIT-013
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CIT-013
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : ReumaNederland
Deal Size : Undisclosed
Deal Type : Funding
Citryll Collaborates on NET Research for Novel Rheumatoid Arthritis Treatments
Details : The proceeds will be used in the clinical development programs of NET-targeting therapies such as Citryll’s lead anti-inflammatory candidate CIT-013, a first-in-class monoclonal antibody.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
March 10, 2024
Lead Product(s) : CIT-013
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : ReumaNederland
Deal Size : Undisclosed
Deal Type : Funding
Lead Product(s) : CIT-013
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Bom Brabant Ventures
Deal Size : $21.0 million
Deal Type : Financing
Details : The proceeds will be used to advance the pre-clinical and clinical development of Citryll’s CIT-013 therapeutic antibody, an inhibitor of neutrophil extracellular traps (NETs) and their formation (NETosis).
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
February 07, 2020
Lead Product(s) : CIT-013
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Bom Brabant Ventures
Deal Size : $21.0 million
Deal Type : Financing